» Articles » PMID: 33999411

Dystrophin Deficiency Impairs Vascular Structure and Function in the Canine Model of Duchenne Muscular Dystrophy

Overview
Journal J Pathol
Specialty Pathology
Date 2021 May 17
PMID 33999411
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy (DMD) is a muscle-wasting disease caused by dystrophin deficiency. Vascular dysfunction has been suggested as an underlying pathogenic mechanism in DMD. However, this has not been thoroughly studied in a large animal model. Here we investigated structural and functional changes in the vascular smooth muscle and endothelium of the canine DMD model. The expression of dystrophin and endothelial nitric oxide synthase (eNOS), neuronal NOS (nNOS), and the structure and function of the femoral artery from 15 normal and 16 affected adult dogs were evaluated. Full-length dystrophin was detected in the endothelium and smooth muscle in normal but not affected dog arteries. Normal arteries lacked nNOS but expressed eNOS in the endothelium. NOS activity and eNOS expression were reduced in the endothelium of dystrophic dogs. Dystrophin deficiency resulted in structural remodeling of the artery. In affected dogs, the maximum tension induced by vasoconstrictor phenylephrine and endothelin-1 was significantly reduced. In addition, acetylcholine-mediated vasorelaxation was significantly impaired, whereas exogenous nitric oxide-induced vasorelaxation was significantly enhanced. Our results suggest that dystrophin plays a crucial role in maintaining the structure and function of vascular endothelium and smooth muscle in large mammals. Vascular defects may contribute to DMD pathogenesis. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Citing Articles

Poor bone health in Duchenne muscular dystrophy: a multifactorial problem beyond corticosteroids and loss of ambulation.

Hurley-Novatny A, Chang D, Murakami K, Wang L, Li H Front Endocrinol (Lausanne). 2024; 15():1398050.

PMID: 39669499 PMC: 11634624. DOI: 10.3389/fendo.2024.1398050.


Endothelial cell signature in muscle stem cells validated by VEGFA-FLT1-AKT1 axis promoting survival of muscle stem cell.

Verma M, Asakura Y, Wang X, Zhou K, Unverdi M, Kann A Elife. 2024; 13.

PMID: 38842166 PMC: 11216748. DOI: 10.7554/eLife.73592.


Cellular interactions and microenvironment dynamics in skeletal muscle regeneration and disease.

Rodriguez C, Timoteo-Ferreira F, Minchiotti G, Brunelli S, Guardiola O Front Cell Dev Biol. 2024; 12:1385399.

PMID: 38840849 PMC: 11150574. DOI: 10.3389/fcell.2024.1385399.


Lethal immunotoxicity in high-dose systemic AAV therapy.

Duan D Mol Ther. 2023; 31(11):3123-3126.

PMID: 37822079 PMC: 10638066. DOI: 10.1016/j.ymthe.2023.10.015.


Re-examination of therapeutic management of muscular dystrophies using a vascular smooth muscle-centered approach.

Preethy S, Yamamoto N, Osaza S, Raghavan K, Dedeepiya V, Iwasaki M J Smooth Muscle Res. 2023; 59:67-80.

PMID: 37673649 PMC: 10482562. DOI: 10.1540/jsmr.59.67.


References
1.
Smith B, Yue Y, Woods P, Kornegay J, Shin J, Williams R . An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest. 2010; 91(2):216-31. PMC: 2999660. DOI: 10.1038/labinvest.2010.146. View

2.
Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A . Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021; 7(1):13. PMC: 10557455. DOI: 10.1038/s41572-021-00248-3. View

3.
Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K . Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet. 2006; 15(14):2266-75. DOI: 10.1093/hmg/ddl151. View

4.
Shin J, Pan X, Hakim C, Yang H, Yue Y, Zhang K . Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther. 2013; 21(4):750-7. PMC: 3616540. DOI: 10.1038/mt.2012.283. View

5.
Harvey R . Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol. 2012; (208):299-316. DOI: 10.1007/978-3-642-23274-9_13. View